Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 27
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
5,031
-3.65%
|
$633,906
$126.0 P/Share
|
|
Apr 24
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
412
-0.3%
|
$51,088
$124.68 P/Share
|
|
Apr 20
2023
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,764
-10.59%
|
$3,845,500
$125.0 P/Share
|
|
Apr 20
2023
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,007
-3.68%
|
$250,875
$125.0 P/Share
|
|
Apr 20
2023
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
2,214
-3.14%
|
$274,536
$124.5 P/Share
|
|
Apr 17
2023
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
2,781
-5.07%
|
$333,720
$120.0 P/Share
|
|
Apr 10
2023
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
393
-0.47%
|
$44,016
$112.35 P/Share
|
|
Apr 03
2023
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,612
-1.86%
|
$415,380
$115.06 P/Share
|
|
Apr 03
2023
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
20,812
-2.03%
|
$2,372,568
$114.64 P/Share
|
|
Mar 23
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
5,442
-3.79%
|
$631,272
$116.4 P/Share
|
|
Mar 16
2023
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
SELL
Open market or private sale
|
Direct |
2,303
-6.42%
|
$264,845
$115.0 P/Share
|
|
Mar 14
2023
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
393
-0.47%
|
$43,623
$111.86 P/Share
|
|
Mar 13
2023
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
SELL
Open market or private sale
|
Direct |
6,229
-14.8%
|
$660,274
$106.27 P/Share
|
|
Mar 13
2023
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
2,782
-4.82%
|
$294,892
$106.27 P/Share
|
|
Mar 13
2023
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
2,010
-2.77%
|
$213,060
$106.27 P/Share
|
|
Mar 10
2023
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,472
-3.67%
|
$718,392
$111.4 P/Share
|
|
Mar 10
2023
|
Sadie Stern EVP, Chief HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,115
-3.45%
|
$678,765
$111.4 P/Share
|
|
Mar 10
2023
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,618
-2.89%
|
$1,067,598
$111.4 P/Share
|
|
Mar 10
2023
|
Donald Abbey EVP Global Business Services I |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,669
-1.8%
|
$1,295,259
$111.4 P/Share
|
|
Mar 10
2023
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,670
-6.61%
|
$1,295,370
$111.4 P/Share
|
|
Mar 10
2023
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,812
-6.85%
|
$534,132
$111.4 P/Share
|
|
Mar 10
2023
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,204
-3.37%
|
$688,644
$111.4 P/Share
|
|
Mar 10
2023
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,109
-1.78%
|
$1,788,099
$111.4 P/Share
|
|
Mar 10
2023
|
Paul R Flynn EVP Global Revenue |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,845
-8.18%
|
$1,869,795
$111.4 P/Share
|
|
Mar 10
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,669
-2.57%
|
$1,295,259
$111.4 P/Share
|
|
Mar 10
2023
|
Barry J. Regan EVP Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,680
-3.7%
|
$630,480
$111.4 P/Share
|
|
Mar 10
2023
|
Kevin R Sayer Chairman, CEO & President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,490
-3.35%
|
$4,161,390
$111.4 P/Share
|
|
Mar 08
2023
|
Teri L Lawver EVP Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,352
+50.0%
|
-
|
|
Mar 08
2023
|
Paul R Flynn EVP Global Revenue |
BUY
Grant, award, or other acquisition
|
Direct |
18,776
+20.13%
|
-
|
|
Mar 08
2023
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
BUY
Grant, award, or other acquisition
|
Direct |
21,769
+31.07%
|
-
|
|
Mar 08
2023
|
Kevin R Sayer Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
54,422
+12.36%
|
-
|
|
Mar 08
2023
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
18,776
+19.37%
|
-
|
|
Mar 08
2023
|
Michael Jon Brown EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,769
+23.65%
|
-
|
|
Mar 08
2023
|
Donald Abbey EVP Global Business Services I |
BUY
Grant, award, or other acquisition
|
Direct |
18,776
+7.87%
|
-
|
|
Mar 08
2023
|
Jereme M Sylvain EVP, Chief Financal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,769
+20.06%
|
-
|
|
Mar 08
2023
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,769
+19.45%
|
-
|
|
Mar 08
2023
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,885
+15.15%
|
-
|
|
Mar 08
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
BUY
Grant, award, or other acquisition
|
Direct |
18,776
+10.79%
|
-
|
|
Mar 08
2023
|
Girish Naganathan EVP Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,776
+27.21%
|
-
|
|
Mar 08
2023
|
Jacob Steven Leach EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,397
+7.65%
|
-
|
|
Mar 06
2023
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
SELL
Open market or private sale
|
Direct |
226
-0.84%
|
$25,764
$114.4 P/Share
|
|
Mar 06
2023
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,144
-3.08%
|
$2,068,416
$114.79 P/Share
|
|
Mar 01
2023
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
38,464
-5.29%
|
$4,231,040
$110.12 P/Share
|
|
Feb 23
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
412
-0.3%
|
$45,732
$111.64 P/Share
|
|
Feb 22
2023
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
2,400
-3.57%
|
$273,600
$114.54 P/Share
|
|
Jan 30
2023
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
56,844
-6.8%
|
$6,025,464
$106.36 P/Share
|
|
Jan 30
2023
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
2,213
-3.59%
|
$234,578
$106.12 P/Share
|
|
Jan 23
2023
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
412
-0.3%
|
$44,084
$107.86 P/Share
|
|
Jan 20
2023
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
45,607
-9.66%
|
$4,788,735
$105.75 P/Share
|
|
Jan 18
2023
|
Kevin R Sayer Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
90,720
+16.11%
|
-
|